The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Open accessAbstract
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“The impact of ConvP therapy on the length of hospital stay was analyzed both with a proportional hazards model for the subdistribution of hospital discharge as proposed by Fine and Gray (1999)56 and by reporting the causespecific hazards using Kaplan–Meier plots.”
MethodDexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · cited 1×
“Although a systematic collection of cultures before inclusion was not required per protocol and current knowledge indicates that viral cultures tend to become negative around 8 days of symptoms, (34, 35) none of the 6 patients from the SoC arm and 1 patient on ConvP had cytopathic effects in culture after 7 days of in…”
BackgroundClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Self-citationvan Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., van den Akker, J. P. C., Endeman, H., Gommers, D. A. M. P. J., Cornelissen, J. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20568-4 · Cited by 838
Self-citationThe Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects
Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., & Cordero, A. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.05.045 · Cited by 730
Cited by
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Klein, S. L., Pekosz, A., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K., Kumar, S., Naik, H. M., Betenbaugh, M. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142004 · Cited by 432
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 420
Self-citationAlhazzani, W., Evans, L., Alshamsi, F., Møller, M. H., Ostermann, M., Prescott, H. C., Arabi, Y. M., Loeb, M., Ng Gong, M., Fan, E., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004899 · Cited by 417
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 367
Metadata
- Authors
- Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., Hassing, R.-J., Bos, J. C., van Pottelberge, G. R., Vlasveld, I. N., Ammerlaan, H. S. M., van Leeuwen – Segarceanu, E. M., Miedema, J., van der Eerden, M., Schrama, T. J., Papageorgiou, G., te Boekhorst, P., Swaneveld, F. H., Mueller, Y. M., Schreurs, M. W. J., van Kampen, J. J. A., Rockx, B., Okba, N. M. A., Katsikis, P. D., Koopmans, M. P. G., Haagmans, B. L., Rokx, C., & Rijnders, B. J. A.
- Venue
- Nature Communications
- Published
- 2021-05-27
- Volume
- 12
- Issue
- 1
- Pages
- 3189-3189
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3111197543
- Cited by
- 347
- References
- 11
- FWCI
- 20.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1038/s41467-021-23469-2
- The paper
- Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., Hassing, R.-J., Bos, J. C., van Pottelberge, G. R., Vlasveld, I. N., Ammerlaan, H. S. M., van Leeuwen – Segarceanu, E. M., Miedema, J., van der Eerden, M., Schrama, T. J., . . . Rijnders, B. J. A. (2021). Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications. https://doi.org/10.1038/s41467-021-23469-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
